2174 related articles for article (PubMed ID: 24849689)
1. Statin-associated incident diabetes: a literature review.
Park ZH; Juska A; Dyakov D; Patel RV
Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
[TBL] [Abstract][Full Text] [Related]
2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
3. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
4. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
[TBL] [Abstract][Full Text] [Related]
5. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Cho Y; Choe E; Lee YH; Seo JW; Choi Y; Yun Y; Wang HJ; Ahn CW; Cha BS; Lee HC; Kang ES
Metabolism; 2015 Apr; 64(4):482-8. PubMed ID: 25312577
[TBL] [Abstract][Full Text] [Related]
6. Statin-Associated Diabetes Mellitus: Review and Clinical Guide.
Backes JM; Kostoff MD; Gibson CA; Ruisinger JF
South Med J; 2016 Mar; 109(3):167-73. PubMed ID: 26954655
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
[TBL] [Abstract][Full Text] [Related]
8. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
[TBL] [Abstract][Full Text] [Related]
9. Statin therapy and risk of developing type 2 diabetes: a meta-analysis.
Rajpathak SN; Kumbhani DJ; Crandall J; Barzilai N; Alderman M; Ridker PM
Diabetes Care; 2009 Oct; 32(10):1924-9. PubMed ID: 19794004
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
Kones R
Drug Des Devel Ther; 2010 Dec; 4():383-413. PubMed ID: 21267417
[TBL] [Abstract][Full Text] [Related]
12. Are statins diabetogenic?
Sampson UK; Linton MF; Fazio S
Curr Opin Cardiol; 2011 Jul; 26(4):342-7. PubMed ID: 21499090
[TBL] [Abstract][Full Text] [Related]
13. Impact of the JUPITER trial on statin prescribing for primary prevention.
Teng JF; Gomes T; Camacho X; Grundy S; Juurlink DN; Mamdani MM
Pharmacotherapy; 2014 Jan; 34(1):9-18. PubMed ID: 23940007
[TBL] [Abstract][Full Text] [Related]
14. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis.
Cui JY; Zhou RR; Han S; Wang TS; Wang LQ; Xie XH
J Clin Pharm Ther; 2018 Aug; 43(4):556-570. PubMed ID: 29733433
[TBL] [Abstract][Full Text] [Related]
15. New onset diabetes mellitus induced by statins: current evidence.
Chrysant SG
Postgrad Med; 2017 May; 129(4):430-435. PubMed ID: 28276790
[TBL] [Abstract][Full Text] [Related]
16. Statins, risk of diabetes, and implications on outcomes in the general population.
Wang KL; Liu CJ; Chao TF; Huang CM; Wu CH; Chen SJ; Chen TJ; Lin SJ; Chiang CE
J Am Coll Cardiol; 2012 Oct; 60(14):1231-8. PubMed ID: 22884288
[TBL] [Abstract][Full Text] [Related]
17. Diabetogenic Action of Statins: Mechanisms.
Carmena R; Betteridge DJ
Curr Atheroscler Rep; 2019 Apr; 21(6):23. PubMed ID: 31037345
[TBL] [Abstract][Full Text] [Related]
18. Risk of incident diabetes among patients treated with statins: population based study.
Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
